Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

5(71.4%)

Phase 3

2(28.6%)

7Total

N/A(5)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06827327Phase 3Completed

LC-Plasma for Preventing URTIs and Reducing Symptoms

Role: collaborator

NCT06837961Phase 3Completed

LC-Plasma on Immune Response and Reducing Symptoms of Upper Respiratory Infectious Diseases

Role: collaborator

NCT07089238Not ApplicableRecruiting

Evaluate the Effects of Citicoline on Mood in Healthy Adults

Role: lead

NCT06906848Not ApplicableCompleted

Evaluate the Effects of Citicoline on Cognitive Performance in Healthy Adults

Role: lead

NCT04967157Not ApplicableCompleted

Cognitive Effects of Citicoline on Attention in Healthy Mean and Women

Role: lead

NCT04090138Not ApplicableCompleted

Setria Performance Blend Supplementation

Role: collaborator

NCT03725241Not ApplicableCompleted

Effects of Glutathione on Immunity in Individuals Training for a Marathon

Role: collaborator

All 7 trials loaded